scholarly journals A Case of Granuloma Annulare Associated with Secukinumab Use

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Lauren Bonomo ◽  
Sara Ghoneim ◽  
Jacob Levitt
Keyword(s):  
Inflammatory Cells ◽  
Granuloma Annulare ◽  
Delayed Type Hypersensitivity ◽  
Necrosis Factor Alpha ◽  
Inflammatory Dermatosis ◽  
Interleukin 17A ◽  
Tissue Degradation ◽  
Factor Alpha ◽  
Connective Tissue Degradation ◽  
Necrosis Factor

Granuloma annulare (GA) is a benign inflammatory dermatosis characterized clinically by dermal papules and annular plaques. The pathogenesis of GA is not well understood, although it is thought to result from a delayed-type hypersensitivity reaction in which inflammatory cells elicit connective tissue degradation. This condition has been seen following the use of several drugs, including tumor necrosis factor-alpha (TNF-α) inhibitors, which paradoxically have also been reported to treat GA. We report the case of a patient who developed GA in association with secukinumab, an interleukin-17A antagonist, and discuss its implications for our understanding of the pathogenesis of GA.

scholarly journals Hyaluronic Acid-Modified and TPCA-1-Loaded Gold Nanocages Alleviate Inflammation

Pharmaceutics ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 143 ◽  
Author(s):  
Jingnan Zhao
Keyword(s):  
Hyaluronic Acid ◽  
Inflammatory Cells ◽  
Oxygen Species ◽  
Necrosis Factor Alpha ◽  
Tnf Α ◽  
Nanogold Particles ◽  
Gold Nanocages ◽  
Factor Alpha ◽  
Anti Inflammatory ◽  
Necrosis Factor

Gold nanocages (AuNCs) are biocompatible and porous nanogold particles that have been widely used in biomedical fields. In this study, hyaluronic acid (HA) and peptide- modified gold nanocages (HA-AuNCs/T/P) loaded with 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1) were prepared to investigate their potential for combating inflammation. TPCA-1 was released from AuNCs, intracellularly when HA was hydrolyzed by hyaluronidase. HA-AuNCs/T/P show a much higher intracellular uptake than AuNCs/T/P, and exhibit a much higher efficacy on the suppression of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) than free TPCA-1, suggesting great improvement to the anti-inflammatory efficacy of TPCA-1 through the application of AuNCs. HA-AuNCs/T/P can also reduce the production of reactive oxygen species in inflammatory cells. This study suggests that HA-AuNCs/T/P may be potential agents for anti-inflammatory treatment, and are worthy of further investigation.

Osthole Improves Acute Pancreatitis Injury by Regulating NF-κB, Nuclear Factor Pathway

2021 ◽  
Vol 19 (4) ◽  
pp. 532-536
Author(s):  
Shifeng Zhu ◽  
Xiaosheng Cai ◽  
Haicheng Dong ◽  
Bing Wang ◽  
Weixing Ying ◽  
...  
Keyword(s):  
Acute Pancreatitis ◽  
Tissue Injury ◽  
Inflammatory Cells ◽  
Protective Role ◽  
Pancreatic Acinar Cells ◽  
Caspase 9 ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Necrosis Factor

We have investigated the protective role of osthole in tissue injury in experimentally induced acute pancreatitis in a rat model. Acute pancreatitis causes moderate to severe interstitial edema, extensive infiltration of inflammatory cells, marked vacuolation of pancreatic acinar cells, necrosis and hemorrhage in pancreatic tissues. Also, the levels of amylase and lipase, diagnostic markers of acute pancreatitis, are elevated with concurrent rise in the pro-inflammatory cytokinestumor necrosis factor-alpha, interleukin-6, and interleukin-1β. The levels of capase-3, caspase-9, cleaved-caspase-3 and cleaved-caspase-9 were also elevated. The phosphorylation of p65 and IκBα was upregulated and the expression of IκBα was downregulated. There was a diminution in all of the aforementioned changes following osthole administration. In conclusion, the results of this study demonstrated that osthole prevents tissue injury in acute pancreatitis through inhibition of the activation of NF-κB pathway, providing a new insight to potential treatment.

scholarly journals Tumor necrosis factor-alpha and the cytokine network in psoriasis

2012 ◽  
Vol 87 (5) ◽  
pp. 673-683 ◽  
Author(s):  
Arles Martins Brotas ◽  
José Marcos Tellas Cunha ◽  
Eduardo Henrique Jorge Lago ◽  
Cristiane Chaves Nascentes Machado ◽  
Sueli Coelho da Silva Carneiro
Keyword(s):  
Langerhans Cells ◽  
Tumor Necrosis ◽  
Inflammatory Cells ◽  
Cytokine Network ◽  
Necrosis Factor Alpha ◽  
Plaque Development ◽  
Infiltrating Cells ◽  
Factor Alpha ◽  
Necrosis Factor

New molecular methods of research have greatly expanded the knowledge about the role of cytokines in several diseases, including psoriasis. The work orchestrated by these peptides is essential for the communication between resident inflammatory cells (keratinocytes and endothelial cells) and infiltrating cells (neutrophils, lymphocytes, Langerhans cells). This is a complex network due to redundancy, synergism and, sometimes, the antagonism of cytokines, which prevents full understanding of the pathogenesis of the disease. Currently, it seems premature to try to establish a main actor, but TNFalpha participates in all stages of psoriatic plaque development, as we shall see.

scholarly journals Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor

2021 ◽  
Vol 29 (2) ◽  
pp. 230949902110122
Author(s):  
Takuya Izumiyama ◽  
Yu Mori ◽  
Itsuki Oizumi ◽  
Soshi Hamada ◽  
Hiroaki Kurishima ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Disease Activity ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Japanese Patients ◽  
Necrosis Factor Alpha ◽  
Interleukin 17A ◽  
Factor Alpha ◽  
Necrosis Factor

Objectives: The patient of severe psoriatic arthritis (PsA) is mainly treated with oral methotrexate, ciclosporin, and anti-tumor necrosis factor-alpha inhibitors (TNFi). Recently, anti-interleukin-17A inhibitors (IL-17Ai) have been used in the treatment of PsA. This study aimed to evaluate the efficacy and safety of IL-17Ai in Japanese patients with PsA compared with those of TNFi. Methods: This was a longitudinal and retrospective study. The study population included 31 Japanese patients with PsA. All enrolled patients fulfilled the Classification Criteria for Psoriatic Arthritis. All patients were treated with TNFi or IL-17Ai. The assessed clinical manifestations were C-reactive protein (CRP)-based Disease Activity Score in 28 Joints (DAS28-CRP), disease activity in psoriatic arthritis (DAPSA), 20% achievement of American College of Rheumatology core set, swollen joint count (SJC), tender joint count (TJC), and visual analog scale (VAS). Functional ability of patients with PsA was analyzed using the modified health assessment questionnaire (mHAQ) score. We evaluated the parameters at baseline and weeks 12, 24, and 52. Results: The change in SJC, TJC, VAS, mHAQ, and DAPSA had no significant difference at weeks 12, 24, and 52. The improvements of CRP and DAS28-CRP were significantly higher in TNFi group only at week 12. The biologics retention rate was significantly higher in TNFi group by the log-rank test. No critical adverse events occurred. Conclusions: Our study presented that IL-17Ai had treatment effects comparable to TNFi. IL-17Ai might have the potential to become an alternative to the previous drug, but more large-scale studies are expected.

scholarly journals Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report

2020 ◽  
Vol 8 ◽  
pp. 2050313X2090456 ◽  
Author(s):  
Reetesh Bose ◽  
Jennifer Beecker
Keyword(s):  
Rare Variants ◽  
Necrosis Factor Alpha ◽  
Post Market Surveillance ◽  
Interleukin 17A ◽  
Potential Association ◽  
Post Market ◽  
Factor Alpha ◽  
Necrosis Factor

Secukinumab was the first fully human anti-interleukin-17a monoclonal antibody and successfully treated moderate-severe psoriasis. These new, targeted, medications are becoming more ubiquitous, but long-term side effects are not fully known. Post-market surveillance is crucial to identify delayed adverse events, analogous to the paradoxical development of pustular psoriasis in a subset of patients treated with the anti-tumor necrosis factor-alpha class drugs. Dyshidrotic eczema and pompholyx are rare variants of dermatitis characterized by vesicles or bullae on the palms, soles and sides of the fingers. The etiology of dyshidrotic eczema is not always known, but medications have been implicated in a minority of patients. Herein, we present two cases of dyshidrotic eczema developing in patients on secukinumab for psoriasis. Extended follow-up and larger numbers of patients are needed to fully understand the potential association between secukinumab and dyshidrotic eczema.

Sign in / Sign up

Export Citation Format

Share Document